A
Here’s a clear summary of NOAH (Neonatal Oral Antibiotics at Home) — an emerging UK NHS quality improvement pathway for neonatal infection management:
🤱 What is NOAH?
NOAH (Neonatal Oral Antibiotics at Home) is a clinical pathway developed in the UK that allows some newborns with suspected early-onset infection (EOI) to finish their antibiotic treatment at home by switching from intravenous (IV) to oral antibiotics after a short period in hospital. (Health Innovation South West)
Instead of a traditional 7-day hospital stay on IV antibiotics, eligible babies are discharged after ~36 hours on oral antibiotics, with appropriate follow-up and support. (Health Innovation South West)
📍 Where it Started
The pathway was introduced as a pilot at the Royal Devon University Healthcare NHS Foundation Trust (Wonford Hospital). (Health Innovation South West)
It was developed in partnership with Health Innovation South West, NIHR Applied Research Collaboration South West Peninsula (PenARC), and the South West Neonatal Network. (Health Innovation South West)
🧪 How It Works (Eligibility & Process)
Babies may be considered for NOAH if all of the following are satisfied: (Health Innovation South West)
At least 36 hours of IV antibiotics have already been given in hospital. (Health Innovation South West)
The baby is clinically well and stable. (Health Innovation South West)
Peak CRP ≤ 50 and falling with good trends (a marker of inflammation). (Health Innovation South West)
Blood and CSF cultures remain negative (no confirmed infection). (Health Innovation South West)
If eligible, the baby switches to oral antibiotics and goes home to complete the course, with planned follow-up (typically telephone contact around Day 5). (Health Innovation South West)
💊 Typical Oral Antibiotics Used
Initially the pathway used oral co-amoxiclav, but since November 2025 this was changed to oral amoxicillin for completing treatment at home. (Health Innovation South West)
🏠 Why NOAH Matters
Benefits reported from pilot and evaluations include: (Health Innovation South West)
✓ Reduced hospital stay
On average, babies avoided ~2.7 hospital days by switching early. (Health Innovation South West)
✓ Improved family experience
Parents reported better bonding, breastfeeding support, and comfort of being home. (nationalhealthexecutive.com)
✓ Lower antibiotic risks
Gentamicin exposure (with potential kidney/hearing risks) was reduced — babies avoided ~2 doses on average. (Health Innovation South West)
✓ Health service impact
A reduction in neonatal unit bed use and potential cost savings (~£65k per year for a single site). (Health Innovation South West)
✓ Positive staff views
97 % of staff involved felt the pathway had positive impacts on babies, families, and hospital services. (The Health Innovation Network -)
🧠 Evidence & Broader Rollout
NOAH has been evaluated and endorsed locally and won the Best Local Project award at the 2025 British Association of Perinatal Medicine (BAPM) Gopi Menon Awards. (Health Innovation South West)
NIHR / PenARC are supporting wider implementation and evaluation across multiple NHS Trusts in England, with plans to expand usage and data collection. (PenARC)
Findings from NOAH have been used in expert testimony to inform updates to national guidance on neonatal infection expected in 2026. (PenARC)
🧑⚕️ What This Is (and Isn’t)
✅ A structured pathway for selected babies to transition safely to oral antibiotics at home.
❌ Not a universal replacement for IV treatment in all neonatal sepsis cases — eligibility and clinician judgment are critical.
❌ Not yet part of official national protocols across all NHS Trusts — uptake varies. (PenARC)
🧩 Summary
NOAH (Neonatal Oral Antibiotics at Home) is an NHS quality improvement initiative allowing some term newborns with suspected early-onset infection to switch from hospital IV antibiotics to oral antibiotics at home after ~36 hours, when they are clinically well and meet strict criteria. It has shown reduced hospital stays, improved family experience, reduced antibiotic exposure and reduced pressure on neonatal units. Pilots in the South West of England are demonstrating feasibility, safety, and wider interest for adoption. (Health Innovation South West)
If you want, I can also outline the specific eligibility checklist and monitoring steps used in NOAH in more detail.
No comments:
Post a Comment